Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023 Aug 17:S0923-7534(23)00800-1. doi: 10.1016/j.annonc.2023.
PMID: 37597578